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This review examines some of the issues encountered in the use of sedation in patients receiving respiratory
support from non-invasive ventilation (NIV). This is an area of critical and intensive care medicine where there are
limited (if any) robust data to guide the development of best practice and where local custom appears to exert a
strong influence on patterns of care.
We examine aspects of sedation for NIV where the current lack of structure may be contributing to missed
opportunities to improve standards of care and examine the existing sedative armamentarium. No single sedative
agent is currently available that fulfils the criteria for an ideal agent but we offer some observations on the relative
merits of different agents as they relate to considerations such as effects on respiratory drive and timing, and
airways patency. The significance of agitation and delirium and the affective aspect(s) of dyspnoea are also
considered.
We outline an agenda for placing the use of sedation in NIV on a more systematic footing, including clearly
expressed criteria and conditions for terminating NIV and structural and organizational conditions for prospective
multicentre trials.
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Use of non-invasive ventilation (NIV) in critical and inten-
sive care has expanded greatly in recent decades in re-
sponse to evidence of its benefits as a means of reducing
dependence on invasive (i.e. with tracheal intubation) ven-
tilation and associated complications, and for the manage-
ment of acute respiratory failure. Adoption and application
of NIV are nevertheless still in a phase of evolution [1]. We
examine this subject with specific reference to the use and
impact of sedation during NIV.
This essay examines a non-exhaustive series of ques-
tions about NIV and the possible role of sedation as a
co-intervention to NIV. The answers - to the extent that
answers are available - emerge from sources that range
from evidence-based medicine to expert opinion. This
range is itself indicative of the incomplete nature of our
current understanding of these matters.* Correspondence: dan.longrois@bch.aphp.fr
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Is sedation universal or mandatory during NIV?
A non-exhaustive inspection of recent reports invites the
conclusion that we as physicians are either indifferent to
or unconcerned about the general topic of sedation during
NIV. The authors of the most recent Cochrane review on
the place of NIV as a weaning strategy for intubated adults
with respiratory failure reported that only one of the stud-
ies they identified used a standardized sedation protocol
before or after initiation of NIV (Table 1) and argued that
the role of sedation as a co-intervention requires specific
investigation in future trials [2-8]. Separately, Scala has
identified only eight small clinical studies of sedation in
NIV, in which a total of 183 patients were assigned to seven
different sedative drug regimens, the effects of which were
assessed by multiple different and non-congruent out-
come parameters (Tables 2 and 3) [9-17].
The drift of these observations appears to be that ei-
ther sedation has not been perceived as a major problem
or opportunity within the wider context of NIV use or
that it has not been studied systematically. The first ofal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Summary of studies making any report of sedation use in the context of NIV in adults with critical illness
(compiled from Burns et al. [2])
Study No. of
patients
Patient characteristics Experimental NIV strategy Sedation status
Hill et al.
2000 [4]




50 Exacerbation of COPD;
mechanical ventilation
for at least 36–48 h
Non-invasive pressure support
on conventional ventilator
delivered with face mask
Sedation reportedly used during NIV but apparently
not protocolized or defined
Prasad et al.
2009 [6]
30 COPD; AHRF Bilevel NIV (pressure mode)
delivered by full face mask
Patients received neuromuscular blocking drugs and
sedatives in immediately preceding phase of invasive
ventilation. Use of sedation during NIV not clear
Rabie Agmy
et al. 2004 [7]
37 Exacerbation of COPD Proportional-assist NIV in
timed mode, delivered by
face or nasal mask
Patients received neuromuscular blocking drugs and
sedatives in immediately preceding phase of invasive





ventilation for at least 48 h
Helmet NIV Sedation reportedly used during NIV but apparently not
protocolized or defined. Rates of continuous sedation during NIV
reported to be similar in both groups (a priori study outcome)
In all the studies, the control strategy used was invasive pressure support.
ARF, acute respiratory failure; AHRF, acute hypercapnic respiratory failure; ST, spontaneous/timed; VPAP, variable positive airway pressure.
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the lack of studies may reflect complaisance (if not com-
placency) about this aspect of NIV technique and pro-
cedure. In any event, both these positions suggest a lack
of attention to the possibilities in this area of NIV.
Narrowly considered, therefore, the answer to our own
question must be “We do not know”. However, the find-
ings of the only survey of practice that we have identified
make it clear that in reality the answer is “No”, as only ≈
25% of NIV patients received sedation (rising to ≈ 40% in
critical care) [18]. Whether or not that percentage repre-
sents an appropriate level of sedation use among recipi-
ents of NIV is just one of many questions to which there
is at present no definitive answer. Inspection of Table 2
suggests that, in those studies where sedation during NIV
was explicitly addressed, the main reason for sedation was
“poor NIV acceptance”. One general aspect of poor NIVTable 2 Studies of sedation in NIV (compiled from Scala [9])
Study No. of patients Indication NIV interface
Rocker et al. [10] 10 ARF FFM
Constantin et al. [11] 13 ARF (n = 10);
AHRF (n = 3)
FFM
Rocco et al. [12] 36 ARF FFM, helmet
Akada et al. [13] 10 ARF FFM
Takasaki et al. [14] 2 SAA FFM
Clouzeau et al. [15] 10 ARF (n = 7);
AHRF (n = 3)
FFM
Senoglu et al. [16] 40 COPD FFM
Huang et al. [17] 62 ACPO FFM, helmet
The last two rows identify randomized controlled trials; other trials were reported n
ACPO, acute cardiogenic pulmonary oedema; ARF, acute respiratory failure; AHRF, a
asthma attack.
*Combined with propofol in three cases. †Combined with morphine in one case anacceptance could be related to the patient-device interface,
i.e. the type of mask that is used and also the assisted ven-
tilation pattern. The choice of NIV interface may influence
the need for sedation. While it can be argued that “the
clinical efficacy of different masks is on average very simi-
lar” [19], our experience is aligned with reports that patient
acceptance is greatest with the least constricting interfaces -
such as the helmet - and declines as more intrusive forms
of mask are used [20]. As for the breathing modes, bilevel
positive airway pressure often produces a need for anxioly-
sis or sedation whereas spontaneous breathing patterns
such as continuous positive airways pressure seldom re-
quire such interventions.
In summary, sedation is not mandatory for NIV but it
may help in specific situations. There are at present no
explicit guiding principles or simple formulae to identify
those situations.Type of sedative Initiation of sedation
Morphine At start of NIV
Remifentanil, midazolam* Poor NIV acceptance
Remifentanil Poor NIV acceptance
Dexmedetomidine† Poor NIV acceptance
Dexmedetomidine Poor NIV acceptance
Propofol Poor NIV acceptance
Dexmedetomidine (n = 20); midazolam (n = 20) At start of NIV
Dexmedetomidine (n = 33); midazolam (n = 29) Poor NIV acceptance
ot to have been controlled. See also Table 3 of this review.
cute hypercapnic respiratory failure; FFM, full face mask; SAA, severe
d with propofol in one case.
Figure 1 Clinical reasoning pathway for the use of sedation
in NIV.
Table 3 Reported dosages of sedatives administered in studies of sedation in NIV (compiled from Scala [9])
Drug No. of patients Dosage Sedation target range
Dexmedetomidine 41 1 μg/kg (bolus); 0.2-0.7 μg/kg/h (infusion) RSS 2-3; RASS 2-4; BIS >85
Midazolam 41 0.05 mg/kg (bolus); 0.05-0.1 mg/kg/h (infusion) RSS 2-3; RASS 2-4; BIS >85
Remifentanil 38 0.025-0.1 μg/kg/min (infusion) RSS 2-3
Propofol 43 0.4 μg/mL (target serum concentration; step-down to 0.2 μg/mL) OAAS/S 3-4
The information in this Table is derived from references 10-17. See also Table 2 of this review.
BIS, bispectral index; OAAS/S, Observer’s Assessment of Alertness/Sedation Scale, RASS, Richmond Agitation and Sedation Scale; RSS, Ramsey Sedation Scale.
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The goals of sedation for a cooperative patient in the in-
tensive care unit (ICU) are to provide analgesia and com-
fort, preserve day/night cycles (including natural sleep)
and avoid nuisances such as ambient light and noise. Add-
itional goals include haemodynamic stability, preservation
of metabolic homeostasis, muscular relaxation, preserva-
tion of diaphragmatic function and attenuation of the
stress/immune response, as well as considerations such as
programmed withdrawal from sedation: they should be no
different during NIV.
Nevertheless, if we regard NIV as a stage in the progres-
sion from intermittent mandatory ventilation to spontan-
eous breathing then there must be a parallel expectation
of a progressive reduction in use of sedation. Two other
points need to be discussed for sedation during NIV.
Firstly, the avoidance of the respiratory depressant effects
of different sedatives; secondly, untoward effects of seda-
tive drugs on the upper airway, a topic that has received
new impetus with increased awareness of obstructive sleep
apnoea [21-24].
Therefore the answer to this question is “Yes”, both
quantitatively (i.e. less ‘deep’ sedation) and qualitatively
in that sedation during NIV must be performed with no/
minimal respiratory depression and no/minimal impair-
ment of the upper airway.
Is sedation per se a factor contributing to the success or
failure of NIV?
Patient acceptance and compliance are essential to the suc-
cess of NIV [13]. Achieving patient acceptance and compli-
ance is a multifaceted exercise, with staff proficiency and
competence being one major influence [25]. However, ac-
ceptance/compliance also relate directly to sedation since
neither can be expected from an insensate patient; nor are
they likely to be forthcoming if the patient is anxious, agi-
tated or disoriented. The necessity of a sedation regimen
that brings the patient to a state of calm, alert cooperation
is clearly implied by these considerations.
Any decision to resort to sedation must be taken as the
last stage in a careful evaluation of the causes of actual or
pending failure, as outlined in Figure 1. It must also take
account of the fact that the likely success of NIV in hypox-
aemic respiratory failure varies considerably according tothe presenting condition [26] and that there is no robust
evidence that sedation will materially affect situations
where the response rate to NIV is intrinsically poor. In-
deed, adding sedation in these situations may be disadvan-
tageous by obscuring a failure of NIV due to underlying
pathology and thus delaying a necessary intubation. Simi-
larly, sedation does not obviate any of the contraindica-
tions to NIV [26].
Nava and Ceriana [25] have partitioned NIV failure into
immediate (< 1 h after commencement), early (1–48 h)
and late (> 48 h) and identified predictors of failure for
each time segment. Factors implicated in immediate NIV
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tor asynchrony”, for which “judicious sedation” is recom-
mended but not characterized in detail.
Sleep disruption was identified as a factor in late NIV
failure [25]. The subject of sleep and sleep disruption in
ICU patients has attracted much research in recent years
(see for example Cabello et al. [27] and Roche Campo
et al. [28]) and one instinctively inclines to the belief that
more normal patterns and quality of sleep are part of
the restoration of health. Whether this is indeed the case
is harder to demonstrate than might be expected but in-
vestigations of the differential effects of sedatives on
electrophysiological dimensions of sleep provide food for
thought [29]. This is, of course, an area where environ-
mental alterations (i.e. minimizing noise and disturb-
ance) may also have an important influence and such
measures should always precede any use of sedatives.
In mechanically ventilated patients, ventilator asynchrony
may adversely affect sleep [30]: the extent to which this dis-
ruptive interaction may work in the opposite direction is
not clear, but there is evidence that, in NIV patients, sleep
is associated with more asynchrony and blood-oxygen desa-
turations than the awake state [31]. These data were ob-
tained from a small cohort of patients receiving long-term
NIV at home and probably do not fully illuminate the situ-
ation of ICU patients receiving both NIV and sedatives.
Choice/type of ventilator is also an important influence
on asynchrony [32,33] and, at least in some cases, is likely
to be more significant than use or non-use of sedatives.
Similarly, ventilators with specific leak compensation
modes and the ability to generate flows ≥ 10 L/min pro-
vide better patient compliance than ICU ventilators with
little leak adaptive capacity.
The answer to the question is thus that we do not
know for certain but that it is unlikely that sedation can
‘rescue’ poorly configured or inappropriate NIV. How-
ever, we hypothesize that adequate sedation can improve
patient comfort in specific situations (see below).
What types of patients/specific situations might benefit
from sedation during NIV?
Reference to English language guidelines for NIV [1] re-
veals that the range of indications for which there is
compelling or even strongly persuasive (Grade 2B or
better) evidence for benefit of NIV is small and may be
summarized as follows.
Acute respiratory failure in the forms of:
 Acute-on-chronic exacerbation of chronic
obstructive pulmonary disease (COPD) with acidotic
and hypercapnoeic features
 Respiratory failure secondary to cardiogenic
pulmonary oedema not arising from shock or acute
coronary syndrome Acute respiratory failure in immunocompromised
patients.
As an adjunct to extubation (but only in expert centres)
for:
 Patients who have COPD
 Patients considered to be at high risk of recurrent
respiratory failure.
We would expect most candidates for sedation during
NIV to come from these categories, and hence to have
certain common presenting features.
As noted above, discomfort, anxiety, agitation, pain,
dyspnoea and the disappointed expectations of the pa-
tient are central in many cases to failure of NIV and
hence also to the decision to use sedation in NIV. Delir-
ium may also be a consideration. Use of sedation in NIV
is, in this context, firmly within the sphere of the clinical
practice guidelines for the management of pain, agita-
tion, and delirium [34] and many of the provisions of
those guidelines are relevant, most especially the obliga-
tion to identify and correct (by non-pharmacological
means if feasible) the causes of pain, agitation, etc.
Agitation and delirium
A first category to consider is patients who are already
agitated before tracheal extubation. A systematic investi-
gation of the causes of anxiety should precede any pre-
scription of a sedative drug. If all otherwise correctable
causes of anxiety are eliminated, and anxiety sine materia
or anxiety due to a decrease/change in sedative regimen
is diagnosed, a case may be made (albeit on the basis
of very slender clinical experience) for dexmedetomidine
as an aid to extubation [35]. The mechanisms underlying
this benefit are not clear and require further, systematic
investigation.
The impact of delirium in patients receiving NIV is ur-
gently in need of attention. The most substantial report we
have found identified a high prevalence of delirium in NIV
patients (≈37%) and linked that to a marked increase in risk
of NIV failure. However, the data on which these findings
were based were described as “scarce and of low quality”
[36]. The role of sedation in the promotion or prevention of
ICU delirium has attracted much comment in recent years
but firm conclusions are still hard to come by. For the mo-
ment, we are unable to go beyond the pain, agitation, and de-
lirium guidelines, which offer weak (Grade 2B) endorsement
for dexmedetomidine in delirium management. “Preven-
tion” of delirium rests substantially on non-pharmacological
methods, particularly early mobilization. Where sedation
is used at all, an emphasis on early mobilization implies a
sedative regimen that facilitates patient participation. (See
Nydahl et al. [37] for a recent perspective on this matter).
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A second category of patients could be those who are
dyspnoeic and anxious, dyspnoea being associated with
delay of extubation [38]. The neuro(patho)physiology
and clinical aspects of dyspnoea have been examined in
detail in a report of the American Thoracic Society that
stratifies dyspnoea according to the quality of the dys-
pnoea experience, the stimuli that evokes it and the af-
ferent neuronal pathways that mediates it [39].
A full discussion of this matter is beyond the scope of
this review but it is worth noting that there is an affective
component of dyspnoea that may be differentiated from
the sensory dimension and might be amenable to inde-
pendent manipulation [40-43]. This signals the import-
ance of identifying and appraising the anxiety component
of dyspnoea. Self-evidently, the cooperation of the patient
is needed for this and any existing sedation regimen must
be adapted to that need.
The affective dimension of dyspnoea may be investi-
gated using either single-item ratings of severity of distress
or unpleasantness or multi-item scales of emotional re-
sponses such as anxiety [39,44,45]. However, there are a
vast array of dyspnoea rating scales, which address differ-
ent aspects of the condition. This is not a reason not to
measure dyspnoea but it is essential to specify which scale
is used for the purpose and to recognize that the nature of
any intervention on dyspnoea is likely to be determined
(or at least influenced) by the aspects of dyspnoea privi-
leged by the chosen scale.
Hence, sedation could be of benefit in situations where
NIV is clearly indicated and where careful evaluation iden-
tifies anxiety, dyspnoea with a high affective dimension or
delirium as barriers to its successful implementation.
Are there evidence-based reasons to prefer specific
sedative drugs during NIV?
There are no robust data to favour any one drug, class
of drugs or protocol over all others. Some of the criteria
that may shape the selection of sedatives for NIV are
summarized in Table 4. No drug or class fully satisfiesTable 4 Properties of sedative drug classes relevant to delive
Sedative Haemodynamic
stability
Analgesia Amnesia Anxiolysis P
Propofol 2 2 2 2 2
Midazolam 3 2 4 2 2
Opioids 4 4 1 2 1
Dexmedetomidine 3 2 2 4 4
Ketamine 4 3 2 1 4
Larger numbers indicate a more satisfactory impact on the nominated property. Th
of different drugs and drug classes, framed in general terms. Hence, the individual
summaries that should not be over-interpreted and which do not necessarily reflec
particular patient.
PONV, postoperative nausea and vomiting; PVD, preservation of ventilatory drive.all these criteria and the final decision rests for the mo-
ment on a sequence of clinical reasoning.
We fully endorse the general presumption against ben-
zodiazepines expressed in the pain, agitation, and delir-
ium guidelines. It is, therefore, a matter of concern that
the data of Devlin et al. suggest that benzodiazepines re-
tain a hold in NIV [18]: however, those data are 7 years
old and may not represent current habits. Fresh research
into prescribing patterns (and the reasoning underpin-
ning them) is desirable: study of the effects of switching
sedatives would also be illuminating. Patterns of sedation
when NIV is delivered on standard wards are undocu-
mented as far as we know and this is another area that
deserves more attention.
Given the pathophysiology of NIV failure, at least three
aspects could be influenced by the choice of sedative
drugs: the patency of the upper airway, respiratory depres-
sion and the affective dimension of dyspnoea. From a
pharmacological point of view, dexmedetomidine appears
to offer the range of qualities best configured to address
these concerns (see for example Hsu et al. [46]). However,
the evidence from controlled trials is not sufficient to give
this conclusion the force of a guideline and additional
considerations (see Table 4) may shape the final selection
of drugs for individual patients. (See also Ho et al. [47] for
a cautionary case report).
Effects on airways patency and the timing and drive of
respiration have been examined earlier in this review and
make a case against benzodiazepines (and perhaps other
γ-aminobutyric acid-ergic agents) and possibly in favour
of dexmedetomidine. Opioids and benzodiazepines de-
crease upper airway diameter and are probably deleterious
during NIV. Propofol has also been shown to increase the
collapsibility of the upper airway in a dose/concentration-
dependent manner [23].
Dexmedetomidine has no direct effects on the patency
of the upper airways. When used as adjunct therapy it
may reduce requirements for opioids (or other sedatives)
and so reduce the likelihood of opioid-induced com-










4 2 2 1 20
2 2 1 1 19
1 1 2 1 20
2 4 4 3 28
1 1 4 1 21
is is primarily a qualitative and relative assessment of the features and benefits
category scores and in particular scores shown in the ‘Total’ column are crude
t the net merits or demerits of particular agents in the circumstances of a
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the respiratory centres.
Ketamine does not cause respiratory depression at doses
given for analgesia or procedural sedation [48]. Further-
more, it decreases airway resistance, improves dynamic
compliance and preserves functional residual capacity, mi-
nute ventilation and tidal volume, while retaining protect-
ive pharyngeal and laryngeal reflexes [49]. Ketamine can
produce hypersalivation and emergence reactions [49]. Be-
cause of its effects on the sympathetic nervous system,
ketamine should not be used in decompensated heart fail-
ure (typically cardiogenic pulmonary oedema in the con-
text of NIV). There is a relatively abundant literature
concerning the use of ketamine for procedural sedation
[50], but experience for sedation during NIV is practically
non-existent.
The answer to this question, therefore, is that sedative
drugs used during NIV should have properties that fur-
ther the goals of sedation during NIV.
From a pharmacological point of view, benzodiazepines
should be avoided: outcome studies in mechanically venti-
lated patients are consistent with that view but there are
no similar trials in NIV to support definitive guidance [51].
(Other recent work provides a timely reminder that with-
out a robust experimental structure it is difficult to make
meaningful comparisons between sedatives [52]).
Dexmedetomidine and ketamine seem to have the
most suitable overall pharmacological profiles. Propofol
and opioids (such as remifentanil) are in an intermediate
position.
Conclusions
Much of the use of sedation in NIV appears to be empir-
ical and is perhaps unstructured. Above all, it appears to
be under-researched: we may be doing better than we
realize or we may be doing less well than we could. With
the continuing growth of NIV as a clinical resource there
is a need for sedation practice to be put on a more sys-
tematic footing.
To that end we propose a three-point plan.
(1) Repeat the international survey of 2007 [18] to
ascertain how, if at all, patterns of sedation use in
NIV have changed in the intervening years and, if
possible, identify the drivers of change.
(2) Review best practice frameworks in NIV to ensure
that guidance includes indications for sedation use,
standardized sedation protocols and clearly
expressed criteria and conditions for terminating
NIV.
(3) Develop at least one (preferably more) prospective
multicentre trial on the effects of sedation in NIV.
Such a trial needs to enrol substantially more
patients than have hitherto been recruited to suchstudies and needs to incorporate the principles
identified in point (2) and a set of unambiguous,
informative and reliable endpoints, including a
predefined and generally accepted definition of NIV
failure. The work of Huang et al. [17] provides a
useful, though not exhaustive, template in this
respect.
In addition to standardization of sedation protocols,
such a trial needs to apply consistent and predefined NIV
modalities. Given the need for substantial numbers of pa-
tients, we anticipate that such a study would, in the first
instance, be confined to patients with acute exacerbation
of COPD, as this is the only category likely to yield suffi-
cient patients within an acceptable and practicable period
of time.
An alternative or additional possibility would be a pro-
spective trial of NIV to prevent acute respiratory failure
in patients recovering from cardiac, abdominal or possibly
thoracic surgery [53,54]. Given that these patients would
be emerging from surgical anaesthesia, there might be a
larger role for sedation and that would facilitate rapid
recruitment.
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